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ratio (ICUR) ranged from 11,921 to 17,215 CNY (1889 to 2728 US dollars, 2012) per 
QALY saved. All of the ICURs were much less than China’s GDP per capita (6247 US 
dollars, 2012). ConClusions: VIA screening at different intervals were all very cost-
effective options for 35-59 years old women in rural China. It is also noted that the 
cost-effective manner of aselected strategy largely depends on the local economic 
status and the performance of such organized program.
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objeCtives: This study aims to estimate incremental cost and utility of Home 
Parenteral Nutrition (HPN) in a heterogeneous group of cancer patients from the 
French public purchaser perspective, as compared with the same patients receiving 
no HPN. Methods: Two economic models, from public French perspective, were 
defined: a 28 day cost-utility model and a lifetime state transition model; both 
models were based on ecological data from an extensive literature search. Four 
health states were used in the second model: Home, two hospitalization states 
and death. Transition to death state was based on survival analysis obtained from 
published summary statistics from two different studies. Functional Assessment 
Cancer Therapy-general (FACT-g) scores, reported in a recently published French 
observational study, were used to compute utility weights in the intervention group 
by applying relevant published algorithms. In the control groups, they were com-
puted by decrementing the baseline utility weight of the intervention group. All 
costs: nutrition costs, resources consumption costs, complication costs and hospi-
talization costs were adapted from published French studies. Both Deterministic 
and Probabilistic Sensitivity Analyses were performed to test uncertainty. Results: 
The cost-utility ratio of HPN is estimated in 508,059 and 182,584 Euro per QALY gain, 
in the 28 day cost-utility model and the lifetime state transition model, respectively. 
DSA showed that survival in the control group and cost of the nutrition were the 
most influential parameters on the cost-utility ratio in both models. The probability 
for cost-effectiveness, considering a willingness to pay (WTP) 87,000 Euro (3XGDP 
per capita in France) for a QALY, was below 1% in both models. ConClusions: 
Final judgment on HPN cost-effectiveness is difficult, even if it seems to be not cost-
effective according to standard WTP. The high cost-utility ratio, which declines with 
increasing survival benefits, should urge clinicians and policy makers to control the 
sources of ineffectiveness.
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objeCtives: Irinotecan is an anti-cancer agent that is used for the treatment of 
metastatic colorectal cancer. Although it prolongs survival, it can cause severe toxic-
ity (e.g. diarrhea and neutropenia) in patients who carry the UGT1A1*28 allele. This 
study evaluates the cost-effectiveness of UGT1A1 genotyping prior to irinotecan-
based chemotherapy from the perspective of the German statutory health insur-
ance. Methods: We develop a decision-analytic Markov model to analyze costs 
and QALYs during a time horizon of six months (two-week cycles). No testing was 
compared to (1) change of chemotherapy to an irinotecan-free regimen, (2) dose 
reduction of irinotecan-based chemotherapy and (3) administration of a prophy-
lactic G-CSF growth factor for patients with a UGT1A1*28 variant. Probability, utility 
and cost parameters used in this study were extracted from published literature. 
Uncertainty was assessed by deterministic and probabilistic sensitivity analy-
ses. Results: Strategy (2) was the cheapest strategy associated with costs of about 
€ 12,600 and effects of approx. 0.32 QALYs. All other three strategies were absolutely 
dominated. Compared to no testing, strategy (2) resulted in only marginal increases 
of QALYs (0.0003) but reduced costs by about € 1,500 per patient. Strategy (1) resulted 
in smaller health gains (0.0002 QALYs) and smaller cost savings (about € 60). Strategy 
(3) yielded approximately the same QALY gains as strategy (2) but at higher costs. In 
the probabilistic analysis, strategy (2) was the optimal strategy in 52% of simulations 
at a threshold of € 50,000 per QALY. Uncertainty for this strategy originated primarily 
from the utility weights and the costs of chemotherapy. ConClusions: Our analy-
sis suggests that UGT1A1 genotyping and subsequent reduction of irinotecan-based 
chemotherapy has a substantial cost-saving potential. Due to the promising results, 
further research, for example in the form of a managed entry agreement would be 
desirable to validate these findings.
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objeCtives: Mutations in BRCA1 and BRCA2 are associated with an increased risk 
of breast and ovarian cancer. If a mutation is detected in women with ovarian 
cancer their unaffected relatives can potentially undergo gene testing and cancer 
risk-reducing surgery. Current UK practice is for any such relative to have access 
to testing. Guidelines also recommend that gene testing should be offered to indi-
viduals with BRCA mutation carrier probability of ≥ 10%, although this is not rou-
tinely implemented. In particular, many eligible women with ovarian cancer are not 
offered BRCA testing. Our aim is to evaluate the long-term cost-effectiveness in the 
UK of providing BRCA testing to women with ovarian cancer and to the unaffected 
female first-degree relatives of those with BRCA mutations. Methods: A Markov 
model with a lifetime horizon was developed to reflect the clinical and economic 
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objeCtives: Ipilimumab was the first compound to substantially prolong survival 
in advanced melanoma. Evaluate the cost-effectiveness of ipilimumab in untreated 
advanced melanoma compared to dacarbazine and vemurafenib from a Swedish 
national payer perspective (TLV/NLT). Methods: A three-state Markov model with 
stable disease, progression and death was developed, estimating costs and ben-
efits over a lifetime horizon. Given a lack of head-to-head data and a connected 
evidence network to allow for a robust NMA, the comparison used two sources of 
data unadjusted for study characteristics. Ipilimumab survival data were based 
on a pooled sample of treatment-naïve patients from clinical trials (n= 78) and 
real-world settings (n= 181), the clinical data package used for EMA submission. 
Parametric extrapolation methods were applied to dacarbazine data from CA184-
024. Mixture modelling was used to extrapolate vemurafenib data from BRIM-III. 
Resource use was taken from a survey of Swedish oncologists (n= 5). EORTC-8D 
utility data from an untreated population were used because they match the popula-
tion of interest. Costs were obtained from official Swedish price lists. Survival and 
utility assumptions were varied in scenario analyses. Results: Ipilimumab was 
associated with a 0.93 QALY gain and an ICER of SEK782,000 (€ 84,000) versus dacar-
bazine. Ipilimumab dominated vemurafenib with a 0.76 QALY gain and a SEK109,000 
(€ 15,000) cost-saving. The unadjusted comparison was the most conservative among 
alternative methods of clinical comparisons explored. The ICER versus dacarbazine 
was SEK521,000 (€ 56,000) using a published survival algorithm (7) and SEK532,000 
(€ 57,000) using a covariate-adjusted survival regression based on the 78-patient 
dataset. A real-world scenario using the patient shares of dacarbazine and vemu-
rafenib was also deemed cost-effective. ConClusions: As in the previously treated 
setting, ipilimumab produces large (> 0.5 year) survival and quality-adjusted sur-
vival gains relative to current treatments. TLV/ NLT considered ipilimumab a cost-
effective treatment for advanced melanoma based on these results.
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objeCtives: Trastuzumab, a targeted therapy, has been widely used in treatment 
of HER2-positive breast cancer because of its proved effectiveness and safety by 
many studies but its economic impact with low-income countries like Viet Nam has 
not been assessed yet. The aim of this study is to evaluate the cost-effectiveness 
of trastuzumab in combination of standard therapy versus standard therapy in 
treatment of metastatic HER2-positive breast cancer. Methods: A Markov model 
was developed with 3 states (stable disease, progressive disease and death) to simu-
late a hypothetical cohort of 1,000 metastatic HER2-positive breast cancer women 
of an average age of 53 year old with the same entry criteria as in the M77001 
study group. Chemotherapy with ACD regimen (Doxorubicin, Cyclophosphamide, 
Docetaxel) was compared with ACD regimen plus trastuzumab. The cycle length of 
model was 1 month and time horizon was lifetime. Both cost and Quality-adjusted 
life-years (QALYs) were discounted annually with 3% discount rate. Probabilistic 
sensitivity analysis was also conducted. Results: Combination of trastuzumab 
and standard therapy compared with standard therapy in treatment of metastatic 
HER2-positive breast cancer resulted in addition of 170.9 million VND (658,8 vs 487,9 
million VND) and 0.81 QALY (1.77 vs 0.96). The incremental cost-effectiveness ratio 
resulted in VND 208,736,442.49/QALY, which was less than willing to Pay (WTP) of 
VietNam in 2013 (VND 253,503,360.00). Therefore, using trastuzumab in treatment 
of metastatic HER2-positive breast cancer women has been considered to be cost-
effective. Sensitivity analyisis showed that the most affecting factors on the cost-
utility of trastuzumab are trastuzumab’s price and patient’s weight. ConClusions: 
Trastuzumab in combination of standard therapy is cost-effective in treatment of 
metastatic HER2-positive breast cancer women in Vietnam. Trastuzumab’s price 
and patient’s weight are the most affecting factors on the cost-effectiveness of 
trastuzumab.
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objeCtives: Chinese government initiated a nation-wide cervical screening pro-
gram, covering 10 million rural women in 221 counties all over the country. The 
objectives of the present study were to compare costs, health outcomes, and cost-
effectiveness of visual inspection with acetic acid (VIA) screening strategies in rural 
China, and to identify optimal screening intervals for policy makers. Methods: 
Markov simulation model was developed to synthesize the evidence of screening 
and treatment practices in rural China, and applied to predict the long-term costs 
and effectiveness for hypothetical cohorts over 20 years of screening. Model was 
validated by calibrating prediction with observation data on age-specific cervical 
cancer mortality and incidence in China. Costs were considered from a societal 
perspective while health effects were mainly expressed as quality-adjusted life 
years (QALY). Both cost and utility were collected on-site and discounted at 5% 
per year. Results: All completing alternatives showed certain benefits due to 
the decreased number of women developing cervical cancer. A trend for shorter 
screening intervals to have greater benefit was found. Under different screening 
intervals, mortality and incidence were expected to be reduced by 6.67-31.74% and 
5.12-23.60%, respectively. Comparing to no screening (status quo), ten-year VIA 
screening was identified as the most cost-effective option, followed by VIA screen-
ing every five-, three- and one year, with corresponding incremental cost-utility 
